Skip to main content

Post-traumatic Stress Disorder

7
Pipeline Programs
19
Companies
20
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
3
0
2
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 23 programs with unclassified modality

Competitive Landscape

17 companies ranked by most advanced pipeline stage

Sage Therapeutics
Sage TherapeuticsMA - Cambridge
1 program
1
Brexanolone Injection [Zulresso]Phase 41 trial
Active Trials
NCT05254405Recruiting20Est. Mar 2026
ViiV Healthcare
ViiV HealthcareNC - Durham
3 programs
2
1
ParoxetinePhase 3
orvepitantPhase 2
paroxetinePhase 2
MSD
MSDIreland - Ballydine
1 program
1
β-adrenergic blocker propranololPhase 3Small Molecule1 trial
Active Trials
NCT02789982Completed364Est. Dec 2019
Pfizer
PfizerNEW YORK, NY
1 program
1
PF-04457845Phase 21 trial
Active Trials
NCT02216097Terminated14Est. Mar 2015
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
3 programs
1
NeuroPace® RNS® SystemPhase 11 trial
Affect Labeling TrainingN/A1 trial
Trigeminal Nerve StimulationN/A1 trial
Active Trials
NCT05924399Completed119Est. Oct 2015
NCT02377089Completed72Est. Oct 2020
NCT04152993Recruiting6Est. Jul 2026
Alliance Pharmaceuticals
4 programs
Common Elements Treatment ApproachN/A1 trial
PARTS ProgramN/A1 trial
PARTS ProgramN/A1 trial
SeroquelN/A1 trial
Active Trials
NCT01856673Completed521Est. Jun 2014
NCT04713501Completed15Est. Jul 2021
NCT05095428Completed82Est. Nov 2023
+1 more trials
Sound Pharmaceuticals
1 program
Behavioral ActivationN/A1 trial
Active Trials
NCT03191760Completed27Est. Feb 2020
March Biosciences
March BiosciencesTX - Houston
1 program
Cognitive Processing TherapyN/A1 trial
Active Trials
NCT01277354Terminated2Est. Jun 2011
BrainsWay
BrainsWayJerusalem, Israel
1 program
Deep TMS SystemN/A1 trial
Active Trials
NCT02479906Terminated203Est. Mar 2020
Utah Medical
Utah MedicalIreland - Dublin
1 program
Recovery after Stress ToolkitN/A1 trial
Active Trials
NCT04830839Completed6Est. Jun 2021
Eppendorf
EppendorfGermany - Hamburg
1 program
ziprasidone, sertralineN/A1 trial
Active Trials
NCT00248261Terminated7Est. Jun 2010
Praxis Precision Medicines
1 program
60 mg PRAX-114 or 40 mg PRAX-114PHASE_21 trial
Active Trials
NCT05260541Terminated11Est. Sep 2022
Precision BioSciences
1 program
60 mg PRAX-114 or 40 mg PRAX-114PHASE_2
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
BI 1358894PHASE_21 trial
Active Trials
NCT05103657Completed318Est. Nov 2023
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
NabiximolsPHASE_2_31 trial
Active Trials
NCT04592159Withdrawn0Est. Mar 2023
UCB Pharma
UCB PharmaBelgium - Brussels
1 program
levetiracetamPHASE_2_31 trial
Active Trials
NCT00413296Completed16Est. Mar 2008
GSK
GSKLONDON, United Kingdom
1 program
ParoxetinePHASE_31 trial
Active Trials
NCT00839397Completed52Est. Jun 2005

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Sage TherapeuticsBrexanolone Injection [Zulresso]
MSDβ-adrenergic blocker propranolol
GSKParoxetine
Jazz PharmaceuticalsNabiximols
UCB Pharmalevetiracetam
Praxis Precision Medicines60 mg PRAX-114 or 40 mg PRAX-114
Boehringer IngelheimBI 1358894
PfizerPF-04457845
Angeles TherapeuticsNeuroPace® RNS® System
Alliance PharmaceuticalsPARTS Program
Alliance PharmaceuticalsPARTS Program
Utah MedicalRecovery after Stress Toolkit
Sound PharmaceuticalsBehavioral Activation
BrainsWayDeep TMS System
Angeles TherapeuticsAffect Labeling Training

Showing 15 of 20 trials with date data

Clinical Trials (20)

Total enrollment: 1,889 patients across 20 trials

NCT05254405Sage TherapeuticsBrexanolone Injection [Zulresso]

An Open Label Pilot Study of IV Brexanolone for the Treatment of Post-Traumatic Stress Disorder

Start: Jun 2023Est. completion: Mar 202620 patients
Phase 4Recruiting
NCT02789982MSDβ-adrenergic blocker propranolol

Using Reconsolidation Blockade to Treat Trauma Related Disorders After Paris Attacks: an Effectiveness Study

Start: May 2016Est. completion: Dec 2019364 patients
Phase 3Completed
NCT00839397GSKParoxetine

BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder

Start: May 2002Est. completion: Jun 200552 patients
Phase 3Completed
NCT04592159Jazz PharmaceuticalsNabiximols

Study of the Safety and Efficacy of Nabiximols Oromucosal Spray Versus Placebo in Patients With Post-traumatic Stress Disorder

Start: Feb 2021Est. completion: Mar 20230
Phase 2/3Withdrawn
NCT00413296UCB Pharmalevetiracetam

Levetiracetam in Post-Traumatic Stress Disorder

Start: Nov 2005Est. completion: Mar 200816 patients
Phase 2/3Completed
NCT05260541Praxis Precision Medicines60 mg PRAX-114 or 40 mg PRAX-114

A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress Disorder

Start: Jan 2022Est. completion: Sep 202211 patients
Phase 2Terminated
NCT05103657Boehringer IngelheimBI 1358894

A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder

Start: Dec 2021Est. completion: Nov 2023318 patients
Phase 2Completed
NCT02216097PfizerPF-04457845

A Study To Assess the Effects Of PF-04457845 On BOLD fMRI In Subjects With Post Traumatic Stress Disorder

Start: Oct 2014Est. completion: Mar 201514 patients
Phase 2Terminated
NCT04152993Angeles TherapeuticsNeuroPace® RNS® System

Responsive Neurostimulation for Post-Traumatic Stress Disorder

Start: Mar 2021Est. completion: Jul 20266 patients
Phase 1Recruiting
NCT05095428Alliance PharmaceuticalsPARTS Program

Program for Alleviating and Resolving Trauma and Stress 2

Start: Apr 2022Est. completion: Nov 202382 patients
N/ACompleted
NCT04713501Alliance PharmaceuticalsPARTS Program

Program for Alleviating and Resolving Trauma and Stress 1

Start: Dec 2020Est. completion: Jul 202115 patients
N/ACompleted
NCT04830839Utah MedicalRecovery after Stress Toolkit

Recovery After Stress Toolkit (ReSeT): Pilot Study

Start: Nov 2020Est. completion: Jun 20216 patients
N/ACompleted
NCT03191760Sound PharmaceuticalsBehavioral Activation

Open Trial of Behavioral Activation and Social Engagement (BASE) for Posttraumatic Stress Disorder (PTSD)

Start: Jun 2017Est. completion: Feb 202027 patients
N/ACompleted
NCT02479906BrainsWayDeep TMS System

A Safety & Efficacy Study With Deep Transcranial Magnetic Stimulation for the Treatment of Post-Traumatic Stress Disorder (PTSD)

Start: Nov 2016Est. completion: Mar 2020203 patients
N/ATerminated
NCT05924399Angeles TherapeuticsAffect Labeling Training

PTSD Affect Labeling Study

Start: Aug 2014Est. completion: Oct 2015119 patients
N/ACompleted
NCT02377089Angeles TherapeuticsTrigeminal Nerve Stimulation

Neuromodulation for Post-Traumatic Stress Disorder

Start: May 2014Est. completion: Oct 202072 patients
N/ACompleted
NCT01856673Alliance PharmaceuticalsCommon Elements Treatment Approach

Evaluation of Two Community-based Mental Health Interventions for Violence-Displaced Afro-Descendants in Colombia.

Start: Jun 2012Est. completion: Jun 2014521 patients
N/ACompleted
NCT01277354March BiosciencesCognitive Processing Therapy

Effectiveness of Cognitive Processing Therapy in Pregnant Women With a History of Pregnancy Loss/Complication

Start: Apr 2010Est. completion: Jun 20112 patients
N/ATerminated
NCT01066156Alliance PharmaceuticalsSeroquel

Post-Traumatic Stress Disorder (PTSD) and Seroquel

Start: Feb 2010Est. completion: Mar 201534 patients
N/ACompleted
NCT00248261Eppendorfziprasidone, sertraline

Ziprasidone and Sertraline in PTSD

Start: Nov 2005Est. completion: Jun 20107 patients
N/ATerminated

Related Jobs

National Sales Director (East)

Compass PathwaysCompass Pathways
United States
4d ago
$230K - $280K/yr

Associate Director, Commercial Forecasting

Compass PathwaysCompass Pathways
New York, United States
6d ago
$160K - $210K/yr

Regional Sales Director (Mid-Atlantic)

Compass PathwaysCompass Pathways
Washington DC, United States
1w ago
$180K - $230K/yr

Regional Sales Director (Texas)

Compass PathwaysCompass Pathways
United States
1w ago
$180K - $230K/yr

Regional Sales Director (Southern California)

Compass PathwaysCompass Pathways
United States
1w ago
$180K - $230K/yr

Regional Sales Director (Pacific Northwest)

Compass PathwaysCompass Pathways
San Francisco, United States
1w ago
$180K - $230K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
2 actively recruiting trials targeting 1,889 patients
19 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.